NPY2R and oropharynx cancer: Methylation of the NPY2R and NPY4R promoters correlated positively with recurrence in patients with oropharyngeal cancers, both individually (odds ratio, 5.20; 95% CI, 1.67–16.2; P = 0.005 and odds ratio, 4.90; 95% CI, 1.07–22.4; P = 0.004, respectively) and together (odds ratio, 5.66; 95 % CI, 1.51–21.3; P = 0.010).